Choosing between a spatial biology core facility, an external service provider, and buying your own platform is usually framed as a volume question. It is really a rate question. The break-even volume that justifies purchase swings by roughly a factor of five depending on whether you can access internal institutional rates or are paying external ones, and most labs never check which side of that line they sit on.
Key Takeaways
|
The Three Models Compared
There are three practical routes to spatial data, and they differ less in what they deliver than in what they demand of you. An institutional core is not simply a cheaper service provider, and a service provider is not simply a slower core. Each carries a distinct set of obligations and a distinct failure mode.
| Institutional Core | External Service Provider | In-House Platform |
Cost basis | Recharge at internal rate | Commercial per-sample pricing | Capital plus recurring |
You supply | Tissue, QC, often histology | Tissue, shipping, data intake plan | Everything |
Turnaround | Depends on core queue | Contractual, often more predictable | Yours to control |
Scheduling control | Shared with other users | None, you are in a pipeline | Full |
Method flexibility | Limited to what the core runs | Limited to the catalog | Whatever you validate |
Data format | Whatever the core returns | Defined by contract, check it | Your choice |
Main failure mode | Queue contention at deadline | Turnaround dependency | Idle capacity and unused capital |
Best fit | Regular volume, flexible timing | Occasional or bursty projects | High, sustained, deadline-driven volume |
Table 1. The three routes to spatial data, compared by what each demands rather than by what each delivers.
Note the asymmetry in the last two rows. A core facility fails you at exactly the moment you most need it, which is when several groups hit a deadline in the same month. An in-house platform fails you slowly and invisibly, as capital depreciates against volume that never arrived. The first failure is painful and recoverable. The second is expensive and hard to admit to.
When Does In-House Actually Break Even?
Break-even is calculable, and the arithmetic is simple enough to state outright. Over a chosen horizon, purchase pays off once the per-section saving multiplied by total sections exceeds the one-time and fixed costs.
The Break-Even Model Break-even sections per year = (Capital + Facility work + (Years × Annual fixed cost)) ÷ (Years × Per-section saving) Per-section saving = Outsourced service rate − In-house reagent cost − (Operator hours × your staff hourly rate) Annual fixed cost covers the service contract, software licenses, and compute. Sequencing and histology drop out of the saving, because you pay for them either way. Your own staff cost is not scaled by the core’s user-category multiplier, since your technicians do not become more expensive because you are an external user at someone else’s facility. |
Populate it with published figures. The Yale Keck Microarray Shared Resource rate card lists 10x Visium CytAssist at $2,141 per 6.5 mm section for internal users as of July 2025, and $467 for the same service when the user supplies reagents, which puts reagent cost at roughly $1,674 per section. Assume two operator hours per section at $56 an hour, and a three-year horizon.
Your Rate Category | Saving per Section | $250k Capital | $500k Capital | $750k Capital |
Internal institutional rate | $355 | 235 sections/yr | 470 sections/yr | 705 sections/yr |
External academic (1.63x) | $1,704 | 49 sections/yr | 98 sections/yr | 147 sections/yr |
Commercial (1.78x) | $2,025 | 42 sections/yr | 83 sections/yr | 124 sections/yr |
Table 2. Break-even section volume over three years, computed from published Yale rates with user-category multipliers derived from published Boston University rates. Excludes annual fixed costs; adding a $20,000 service contract raises the internal $500k figure from 470 to 526.
The spread in that table is the finding. If you can send samples to your own institution’s core at internal rates, buying a platform requires several hundred sections a year to justify, which is a genuinely high bar and more than many labs will ever run. If you are an unaffiliated academic or a commercial lab paying external rates, break-even arrives at volumes a single well-funded program can reach. Two labs with identical science and identical sample counts can therefore reach opposite conclusions, entirely because of institutional affiliation.
Run the model on your own quoted capital figure and rate category using the cost estimator in the spatial biology cost breakdown, which reports break-even volume directly. Two honest caveats apply to any version of this arithmetic. It excludes recharge revenue if you intend to serve other groups, and it excludes the cost of hiring, which can be substantial and is rarely recovered inside three years.
Turnaround and Control Trade-offs
Cost is the argument managers reach for and rarely the one that decides it. Control is. An in-house platform runs when you schedule it, which matters when a grant resubmission deadline is fixed and a core facility queue is not. Outsourcing converts an operational risk into a contractual one, which is sometimes an improvement and sometimes not.
Weigh three things honestly. First, how often has timing actually blocked you, as opposed to how often it felt inconvenient? Second, does the provider or core commit to turnaround contractually, or is the quoted time aspirational? Third, what is your recovery path when a run fails, because a failed section at a provider means shipping more tissue and waiting again, while a failed run in-house means repeating it next week. If your tissue is irreplaceable, that difference matters more than any per-section figure.
Lab Management Certificate
The Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Method flexibility belongs in the same calculation. A core runs the assays it has validated, and a provider sells the catalog it has. If your science needs a custom panel or an unusual tissue type, in-house capability buys you the freedom to develop it, and outsourcing buys you a polite refusal.
Who Owns the Data, and What About IP?
Settle this before the first sample ships, not after the first interesting result. These questions are contractual rather than technical, and they are much easier to negotiate while the provider is still selling to you.
- Who owns the raw data, the processed data, and any derived analysis? These can be treated differently in the same agreement.
- How long does the provider retain your data, and can you compel deletion?
- Can the provider reuse your data, in aggregate or otherwise, for method development or benchmarking?
- What format is returned, and does it include the raw output or only processed results? Ask for a sample dataset from a previous project before signing.
- If the work leads to a patentable finding, does the agreement create any provider claim or obligation?
- For human tissue, does the arrangement satisfy your consent and ethics approvals, including any restriction on sending samples off-site or across borders?
An institutional core usually simplifies most of these, because the data stays inside your institution and existing agreements cover it. That is a real advantage and is rarely priced into comparisons. It is not automatic though, so confirm it rather than assuming. None of the above is legal advice, and anything involving human tissue or patentable findings should go past your institution’s contracts or technology transfer office before you sign.
Interested in life sciences?
A Decision Path
Work through these in order. The first condition that applies gives you your answer.
If This Is True | Then |
You have not run spatial before, or tissue quality is unproven | Outsource. Learn what your samples actually yield before committing anything |
Volume is occasional, bursty, or tied to one project | Outsource, or use a core if one is available at internal rates |
An institutional core offers internal rates and timing is flexible | Use the core. Break-even on purchase is several hundred sections a year |
Volume is regular but you have no analyst with allocated time | Use the core or a provider. Close the analyst gap before buying |
Deadlines are fixed and core queue contention has already cost you | Build the case for in-house, leading on control rather than cost |
Your science needs custom panels or unusual tissue types | Build the case for in-house. Catalogs will not accommodate you |
Volume exceeds break-even at your rate category and an analyst is in place | Buy. Take the figures from your own quotes, not from this table |
Table 3. Decision path. The most common correct answer for a lab new to spatial is the first row.
Before acting on the last two rows, confirm the lab can actually support a platform using the spatial biology readiness assessment, then build the justification following how to build a business case for spatial biology. If the conclusion is a shared facility, the operational side of running one is covered in Managing a Spatial Biology Core Facility: Scheduling, Chargebacks, and Access, and general core practice, including the rolling capital planning list, is described well in this account of managing an analytical core facility.
What Should Your First Spatial Project Look Like?
Outsourced, small, and scoped to answer an operational question as much as a scientific one. Send enough tissue to learn whether your fixation and storage history support the assay, whether the data volume matches what you were told, and whether your own people can do anything useful with the output once it arrives. Those three findings are worth more than the pilot data itself, and they are the evidence any later purchase request will rest on.
Then log the demand. Every subsequent inquiry, sample count, and grant aim that names a spatial method becomes part of the case. Programs that phase this way tend to get approved faster when they finally ask, because the analysis is already done and the volume is measured rather than forecast. The full sequencing of that approach is set out in building a spatial biology program: strategy, budget, and ROI, and the operational picture across the whole workflow in the manager's guide to evaluating, implementing, and scaling spatial technologies.
This article was produced under Lab Manager's AI Editorial Guidelines.
